An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer

Advances in Biological Regulation

Volumn 55, Issue , 2014, Pages 1-14

  Maertens, Ophélia ^a,b   Cichowski, Karen ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

DAB2IP; GAP; GTPase activating protein; IQGAP; NF1; RAS; RAS GAP; RASAL2; Therapeutic resistance

Indexed keywords

CARRIER PROTEIN; DAB2IP PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; IQGAP2 PROTEIN, HUMAN; NEUROFIBROMIN; RASAL2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; GENES, NEUROFIBROMATOSIS 1; GTPASE-ACTIVATING PROTEINS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; NEOPLASMS; NEUROFIBROMIN 1; RAS GTPASE-ACTIVATING PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84901433444     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2014.04.002     Document Type: Review

References (138)

1. Agazie Y.M., Hayman M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003, 23:7875-7886.
2. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990, 63:851-859.
3. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
4. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-715.
5. Beauchamp E.M., Woods B.A., Dulak A.M., Tan L., Xu C., Gray N.S., et al. Acquired resistance to dasatinib in lung Cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther 2014, 13:475-482.
6. Berger R., Febbo P.G., Majumder P.K., Zhao J.J., Mukherjee S., Signoretti S., et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004, 64:8867-8875.
7. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003, 1603:47-82.
8. Bernards A., Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol 2004, 14:377-385.
9. Bernards A., Settleman J. GAPs in growth factor signalling. Growth Factors 2005, 23:143-149.
10. Bos J.L., Rehmann H., Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129:865-877.
11. Boudry-Labis E., Roche-Lestienne C., Nibourel O., Boissel N., Terre C., Perot C., et al. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. Am J Hematol 2013, 88:306-311.
12. Bourguignon L.Y., Gilad E., Rothman K., Peyrollier K. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. JBiol Chem 2005, 280:11961-11972.
13. Brems H., Chmara M., Sahbatou M., Denayer E., Taniguchi K., Kato R., et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007, 39:1120-1126.
14. Brill S., Li S., Lyman C.W., Church D.M., Wasmuth J.J., Weissbach L., et al. The Ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol 1996, 16:4869-4878.
15. Chang T., Krisman K., Theobald E.H., Xu J., Akutagawa J., Lauchle J.O., et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. JClin Invest 2013, 123:335-339.
16. Chen H., Tu S.W., Hsieh J.T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. JBiol Chem 2005, 280:22437-22444.
17. Cheok C.F., Verma C.S., Baselga J., Lane D.P. Translating p53 into the clinic. Nat Rev Clin Oncol 2011, 8:25-37.
18. Cichowski K., Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593-604.
19. Cichowski K., Santiago S., Jardim M., Johnson B.W., Jacks T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 2003, 17:449-454.
20. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176.
21. Cooper J.A., Kashishian A. Invivo binding properties of SH2 domains from GTPase-activating protein and phosphatidylinositol 3-kinase. Mol Cell Biol 1993, 13:1737-1745.
22. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., et al. Anegative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
23. D'Angelo I., Welti S., Bonneau F., Scheffzek K. Anovel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. EMBO Rep 2006, 7:174-179.
24. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005, 65:2755-2760.
25. Davoli T., Xu A.W., Mengwasser K.E., Sack L.M., Yoon J.C., Park P.J., et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 2013, 155:948-962.
26. de Bruin E.C., Cowell C.F., Warne P.H., Jiang M., Saunders R.E., Melnick M.A., et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 2014, 4:606-619.
27. De Raedt T., Walton Z., Yecies J.L., Li D., Chen Y., Malone C.F., et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011, 20:400-413.
28. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-273.
29. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
30. Dong P., Nabeshima K., Nishimura N., Kawakami T., Hachisuga T., Kawarabayashi T., et al. Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas. Cancer Lett 2006, 243:120-127.
31. Dote H., Toyooka S., Tsukuda K., Yano M., Ota T., Murakami M., et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 2005, 92:1117-1125.
32. Dote H., Toyooka S., Tsukuda K., Yano M., Ouchida M., Doihara H., et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004, 10:2082-2089.
33. Eerola I., Boon L.M., Mulliken J.B., Burrows P.E., Dompmartin A., Watanabe S., et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003, 73:1240-1249.
34. Ekman S., Thuresson E.R., Heldin C.H., Ronnstrand L. Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding. Oncogene 1999, 18:2481-2488.
35. Erickson J.W., Cerione R.A., Hart M.J. Identification of an actin cytoskeletal complex that includes IQGAP and the Cdc42 GTPase. JBiol Chem 1997, 272:24443-24447.
36. Fantl W.J., Escobedo J.A., Martin G.A., Turck C.W., del Rosario M., McCormick F., et al. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 1992, 69:413-423.
37. Feng L., Yunoue S., Tokuo H., Ozawa T., Zhang D., Patrakitkomjorn S., et al. PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin. FEBS Lett 2004, 557:275-282.
38. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39:D945-D950.
39. Friedman E., Gejman P.V., Martin G.A., McCormick F. Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. Nat Genet 1993, 5:242-247.
40. Fukata M., Kuroda S., Nakagawa M., Kawajiri A., Itoh N., Shoji I., et al. Cdc42 and Rac1 regulate the interaction of IQGAP1 with beta-catenin. JBiol Chem 1999, 274:26044-26050.
41. Fukata M., Watanabe T., Noritake J., Nakagawa M., Yamaga M., Kuroda S., et al. Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170. Cell 2002, 109:873-885.
42. Gioeli D., Mandell J.W., Petroni G.R., Frierson H.F., Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999, 59:279-284.
43. Guo H.F., Tong J., Hannan F., Luo L., Zhong Y. Aneurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 2000, 403:895-898.
44. Ho Y.D., Joyal J.L., Li Z., Sacks D.B. IQGAP1 integrates Ca2+/calmodulin and Cdc42 signaling. JBiol Chem 1999, 274:464-470.
45. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., et al. Alandscape of driver mutations in melanoma. Cell 2012, 150:251-263.
46. Hollstein P.E., Cichowski K. Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov 2013, 3:880-893.
47. Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
48. Hu X., Stern H.M., Ge L., O'Brien C., Haydu L., Honchell C.D., et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009, 7:511-522.
49. Izawa I., Tamaki N., Saya H. Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP-dependent protein kinase. FEBS Lett 1996, 382:53-59.
50. Jacks T., Shih T.S., Schmitt E.M., Bronson R.T., Bernards A., Weinberg R.A. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994, 7:353-361.
51. Jameson K.L., Mazur P.K., Zehnder A.M., Zhang J., Zarnegar B., Sage J., et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 2013, 19:626-630.
52. Jeong J.H., Wang Z., Guimaraes A.S., Ouyang X., Figueiredo J.L., Ding Z., et al. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 2008, 3:e3949.
53. Jessen W.J., Miller S.J., Jousma E., Wu J., Rizvi T.A., Brundage M.E., et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. JClin Invest 2013, 123:340-347.
54. Jin H., Wang X., Ying J., Wong A.H., Cui Y., Srivastava G., et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci U S A 2007, 104:12353-12358.
55. Jin S.H., Akiyama Y., Fukamachi H., Yanagihara K., Akashi T., Yuasa Y. IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer 2008, 122:1040-1046.
56. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005, 102:8573-8578.
57. Joseph N.M., Mosher J.T., Buchstaller J., Snider P., McKeever P.E., Lim M., et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008, 13:129-140.
58. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531.
59. Kazlauskas A., Ellis C., Pawson T., Cooper J.A. Binding of GAP to activated PDGF receptors. Science 1990, 247:1578-1581.
60. Kim H.J., Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol 2004, 5:441-450.
61. Kolfschoten I.G., van Leeuwen B., Berns K., Mullenders J., Beijersbergen R.L., Bernards R., et al. Agenetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005, 121:849-858.
62. Kourea H.P., Orlow I., Scheithauer B.W., Cordon-Cardo C., Woodruff J.M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999, 155:1855-1860.
63. Krauthammer M., Kong Y., Ha B.H., Evans P., Bacchiocchi A., McCusker J.P., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012, 44:1006-1014.
64. Kuroda S., Fukata M., Nakagawa M., Fujii K., Nakamura T., Ookubo T., et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science 1998, 281:832-835.
65. Lackner M.R., Wilson T.R., Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012, 8:999-1014.
66. Lau N., Feldkamp M.M., Roncari L., Loehr A.H., Shannon P., Gutmann D.H., et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. JNeuropathol Exp Neurol 2000, 59:759-767.
67. Le L.Q., Liu C., Shipman T., Chen Z., Suter U., Parada L.F. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res 2011, 71:4686-4695.
68. Legius E., Dierick H., Wu R., Hall B.K., Marynen P., Cassiman J.J., et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosom Cancer 1994, 10:250-255.
69. Legius E., Marchuk D.A., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993, 3:122-126.
70. von Lintig F.C., Dreilinger A.D., Varki N.M., Wallace A.M., Casteel D.E., Boss G.R. Ras activation in human breast cancer. Breast Cancer Res Treat 2000, 62:51-62.
71. Liu D., Yang C., Bojdani E., Murugan A.K., Xing M. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. JNatl Cancer Inst 2013, 105:1617-1627.
72. Maertens O., De Schepper S., Vandesompele J., Brems H., Heyns I., Janssens S., et al. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet 2007, 81:243-251.
73. Maertens O., Johnson B., Hollstein P., Frederick D.T., Cooper Z.A., Messiaen L., et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013, 3:338-349.
74. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002, 8:1168-1171.
75. Margolis B., Li N., Koch A., Mohammadi M., Hurwitz D.R., Zilberstein A., et al. The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma. EMBO J 1990, 9:4375-4380.
76. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843-849.
77. Mayes D.A., Rizvi T.A., Cancelas J.A., Kolasinski N.T., Ciraolo G.M., Stemmer-Rachamimov A.O., et al. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res 2011, 71:4675-4685.
78. McDonald K.L., O'Sullivan M.G., Parkinson J.F., Shaw J.M., Payne C.A., Brewer J.M., et al. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. JNeuropathol Exp Neurol 2007, 66:405-417.
79. McGillicuddy L.T., Fromm J.A., Hollstein P.E., Kubek S., Beroukhim R., De Raedt T., et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009, 16:44-54.
80. McLaughlin S.K., Olsen S.N., Dake B., De Raedt T., Lim E., Bronson R.T., et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 2013, 24:365-378.
81. Mendes-Pereira A.M., Sims D., Dexter T., Fenwick K., Assiotis I., Kozarewa I., et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A 2012, 109:2730-2735.
82. Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010, 16:286-294.
83. Mueller H., Flury N., Eppenberger-Castori S., Kueng W., David F., Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000, 89:384-388.
84. Nabeshima K., Shimao Y., Inoue T., Koono M. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett 2002, 176:101-109.
85. Nielsen G.P., Stemmer-Rachamimov A.O., Ino Y., Moller M.B., Rosenberg A.E., Louis D.N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999, 155:1879-1884.
86. Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C., et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014, 74:2340-2350.
87. Ohta M., Seto M., Ijichi H., Miyabayashi K., Kudo Y., Mohri D., et al. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 2009, 136:206-216.
88. Ouyang X., Jessen W.J., Al-Ahmadie H., Serio A.M., Lin Y., Shih W.J., et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008, 68:2132-2144.
89. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
90. Ren J.G., Li Z., Sacks D.B. IQGAP1 modulates activation of B-Raf. Proc Natl Acad Sci U S A 2007, 104:10465-10469.
91. Riccardi V.M. Neurofibromatosis: phenotype, Natural History, and Pathogenesis 1992.
92. Roy M., Li Z., Sacks D.B. IQGAP1 binds ERK2 and modulates its activity. JBiol Chem 2004, 279:17329-17337.
93. Roy M., Li Z., Sacks D.B. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling. Mol Cell Biol 2005, 25:7940-7952.
94. Rutkowski J.L., Wu K., Gutmann D.H., Boyer P.J., Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 2000, 9:1059-1066.
95. Schmidt V.A., Chiariello C.S., Capilla E., Miller F., Bahou W.F. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol 2008, 28:1489-1502.
96. Schwartz Y.B., Pirrotta V. Anew world of Polycombs: unexpected partnerships and emerging functions. Nat Rev Genet 2013, 14:853-864.
97. Serra E., Rosenbaum T., Winner U., Aledo R., Ars E., Estivill X., et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000, 9:3055-3064.
98. Seto M., Ohta M., Ikenoue T., Sugimoto T., Asaoka Y., Tada M., et al. Reduced expression of RAS protein activator like-1 in gastric cancer. Int J Cancer 2011, 128:1293-1302.
99. Shannon K.M., O'Connell P., Martin G.A., Paderanga D., Olson K., Dinndorf P., et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. NEngl J Med 1994, 330:597-601.
100. Shen M.M., Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007, 67:6535-6538.
101. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008, 647:21-29.
102. Sivaraman V.S., Wang H., Nuovo G.J., Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. JClin Invest 1997, 99:1478-1483.
103. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
104. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296.
105. Stowe I.B., Mercado E.L., Stowe T.R., Bell E.L., Oses-Prieto J.A., Hernandez H., et al. Ashared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev 2012, 26:1421-1426.
106. TCGA Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
107. TCGA Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
108. TCGA Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
109. Tokuo H., Yunoue S., Feng L., Kimoto M., Tsuji H., Ono T., et al. Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of N(G),N(G)-dimethylarginine dimethylaminohydrolase. FEBS Lett 2001, 494:48-53.
110. Tong J., Hannan F., Zhu Y., Bernards A., Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 2002, 5:95-96.
111. Trahey M., Wong G., Halenbeck R., Rubinfeld B., Martin G.A., Ladner M., et al. Molecular cloning of two types of GAP complementary DNA from human placenta. Science 1988, 242:1697-1700.
112. Upadhyaya, M., and Cooper, D. N. (2012). Neurofibromatosis Type 1, (Berlin Heidelberg: Springer-Verlag).
113. Van Allen E.M., Wagle N., Sucker A., Treacy D.J., Johannessen C.M., Goetz E.M., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
114. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176-2179.
115. Vogel U.S., Dixon R.A., Schaber M.D., Diehl R.E., Marshall M.S., Scolnick E.M., et al. Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature 1988, 335:90-93.
116. Walker J.A., Gouzi J.Y., Long J.B., Huang S., Maher R.C., Xia H., et al. Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet 2013, 9:e1003958.
117. Wang S., Watanabe T., Noritake J., Fukata M., Yoshimura T., Itoh N., et al. IQGAP3, a novel effector of Rac1 and Cdc42, regulates neurite outgrowth. JCell Sci 2007, 120:567-577.
118. Wang T., Wei J.J., Sabatini D.M., Lander E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014, 343:80-84.
119. Wang X.X., Li X.Z., Zhai L.Q., Liu Z.R., Chen X.J., Pei Y. Overexpression of IQGAP1 in human pancreatic cancer. Hepatobiliary Pancreat Dis Int 2013, 12:540-545.
120. Weissbach L., Settleman J., Kalady M.F., Snijders A.J., Murthy A.E., Yan Y.X., et al. Identification of a human rasGAP-related protein containing calmodulin-binding motifs. JBiol Chem 1994, 269:20517-20521.
121. Welti S., Fraterman S., D'Angelo I., Wilm M., Scheffzek K. The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex. JMol Biol 2007, 366:551-562.
122. White C.D., Brown M.D., Sacks D.B. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009, 583:1817-1824.
123. White C.D., Erdemir H.H., Sacks D.B. IQGAP1 and its binding proteins control diverse biological functions. Cell Signal 2012, 24:826-834.
124. White C.D., Khurana H., Gnatenko D.V., Li Z., Odze R.D., Sacks D.B., et al. IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol 2010, 10:125.
125. Whittaker S.R., Theurillat J.P., Van Allen E., Wagle N., Hsiao J., Cowley G.S., et al. Agenome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013, 3:350-362.
126. Wu J., Williams J.P., Rizvi T.A., Kordich J.J., Witte D., Meijer D., et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008, 13:105-116.
127. Wu K., Liu J., Tseng S.F., Gore C., Ning Z., Sharifi N., et al. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 2014, 33:1954-1963.
128. Xie D., Gore C., Liu J., Pong R.C., Mason R., Hao G., et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 2010, 107:2485-2490.
129. Xu G.F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990, 63:835-841.
130. Xu W., Mulligan L.M., Ponder M.A., Liu L., Smith B.A., Mathew C.G., et al. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosom Cancer 1992, 4:337-342.
131. Yang X.Y., Guan M., Vigil D., Der C.J., Lowy D.R., Popescu N.C. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 2009, 28:1401-1409.
132. Yano M., Toyooka S., Tsukuda K., Dote H., Ouchida M., Hanabata T., et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005, 113:59-66.
133. Yu J., Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., et al. Apolycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007, 67:10657-10663.
134. Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W. AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. JBiol Chem 2004, 279:44955-44965.
135. Zhang X., Li N., Li X., Zhao W., Qiao Y., Liang L., et al. Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. JGastroenterol Hepatol 2012, 27:1117-1125.
136. Zheng H., Chang L., Patel N., Yang J., Lowe L., Burns D.K., et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 2008, 13:117-128.
137. Zhu Y., Ghosh P., Charnay P., Burns D.K., Parada L.F. Neurofibromas in NF1: schwann cell origin and role of tumor environment. Science 2002, 296:920-922.
138. Zhu Y., Guignard F., Zhao D., Liu L., Burns D.K., Mason R.P., et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005, 8:119-130.